BofA downgraded Erasca (ERAS) to Underperform from Buy with a price target of $1.50, down from $4.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca downgraded to Equal Weight from Overweight at Morgan Stanley
- Cautious Outlook on Erasca Due to Strategic Shifts and Delayed Clinical Data
- Erasca’s Strategic Advancements in RAS Programs Justify Buy Rating
- Erasca Reports Progress and Financial Stability in Q2 2025
- Erasca files $500M mixed securities shelf